Although we previously postulated that IGF-I administration may exert a beneficial effect in all types of ataxia through its wide neuroprotective activities [16], in the case of FRDA a disease-modifying effect of IGF-I may be envisaged if it improves frataxin function by modulating mitochondrial activity. The gene discussed is FXN; the disease is cerebellar ataxia.